Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study. - Archive ouverte HAL
Journal Articles Br J Anaesth Year : 2022

Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.

Gabriela Moyanotidou
  • Function : Author
Benjamin Constant
  • Function : Author
Françoise Broisin
  • Function : Author
Agnès L. Gouez
  • Function : Author
Rémi Favier
  • Function : Author
Edith Peynaud
  • Function : Author
Cyril Huissoud
  • Function : Author
  • PersonId : 888415
Charles Garabedian
Frédéric J. Mercier
  • Function : Author
Catherine Barre-Drouard
  • Function : Author
Max Gonzalez Estevez
  • Function : Author
Julien Corouge
  • Function : Author
Anne-Sophie Baptiste
  • Function : Author
  • PersonId : 1327969
Anne-Frédérique Dalmas
  • Function : Author

Abstract

Background The optimal dose of tranexamic acid to inhibit hyperfibrinolysis in postpartum haemorrhage is unclear. Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Cesarean Delivery (TRACES) was a double-blind, placebo-controlled, randomised, multicentre dose-ranging study to determine the dose–effect relationship for two regimens of intravenous tranexamic acid vs placebo. Methods Women experiencing postpartum haemorrhage during Caesarean delivery were randomised to receive placebo (n=60), tranexamic acid 0.5 g (n=57), or tranexamic acid 1 g i.v. (n=58). Biomarkers of fibrinolytic activation were assayed at five time points, with inhibition of hyperfibrinolysis defined as reductions in the increase over baseline in D-dimer and plasmin–antiplasmin levels and in the plasmin peak time. Results In the placebo group, hyperfibrinolysis was evidenced by a mean increase over baseline [95% confidence interval] of 93% [68–118] for D-dimer level at 120 min and 56% [25–87] for the plasmin–antiplasmin level at 30 min. A dose of tranexamic acid 1 g was associated with smaller increases over baseline (D-dimers: 38% [13–63] [P=0.003 vs placebo]; plasmin–antiplasmin: –2% [–32 to 28] [P=0.009 vs placebo]). A dose of tranexamic acid 0.5 g was less potent, with non-significant reductions (D-dimers: 58% [32–84] [P=0.06 vs placebo]; plasmin–antiplasmin: 13% [18–43] [P=0.051]). Although both tranexamic acid doses reduced the plasmin peak, reduction in plasmin peak time was significant only for the 1 g dose of tranexamic acid. Conclusions Fibrinolytic activation was significantly inhibited by a dose of intravenous tranexamic acid 1 g but not 0.5 g. Pharmacokinetic–pharmacodynamic modelling of these data might identify the best pharmacodynamic monitoring criteria and the optimal tranexamic acid dosing regimen for treatment of postpartum haemorrhage.
Fichier principal
Vignette du fichier
Tranexamic-acid-dose–response-relationship-.pdf (354.44 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04144301 , version 1 (28-06-2023)

Licence

Identifiers

Cite

Anne-Sophie Ducloy-Bouthors, Sixtine Gilliot, Maeva Kyheng, David Faraoni, Alexandre Turbelin, et al.. Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during Caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study.. Br J Anaesth, 2022, Br J Anaesth, 129 (6), pp.937-945. ⟨10.1016/j.bja.2022.08.033⟩. ⟨hal-04144301⟩
95 View
59 Download

Altmetric

Share

More